GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Ocular Therapeutix Inc (NAS:OCUL) » Definitions » Beneish M-Score
中文

Ocular Therapeutix (Ocular Therapeutix) Beneish M-Score : -2.76 (As of Apr. 24, 2024)


View and export this data going back to 2014. Start your Free Trial

What is Ocular Therapeutix Beneish M-Score?

The zones of discrimination for M-Score is as such:

An M-Score of equal or less than -1.78 suggests that the company is unlikely to be a manipulator.
An M-Score of greater than -1.78 signals that the company is likely to be a manipulator.

Good Sign:

Beneish M-Score -2.76 no higher than -1.78, which implies that the company is unlikely to be a manipulator.

The historical rank and industry rank for Ocular Therapeutix's Beneish M-Score or its related term are showing as below:

OCUL' s Beneish M-Score Range Over the Past 10 Years
Min: -3.81   Med: -2.2   Max: 2.14
Current: -2.76

During the past 12 years, the highest Beneish M-Score of Ocular Therapeutix was 2.14. The lowest was -3.81. And the median was -2.20.


Ocular Therapeutix Beneish M-Score Historical Data

The historical data trend for Ocular Therapeutix's Beneish M-Score can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Ocular Therapeutix Beneish M-Score Chart

Ocular Therapeutix Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Beneish M-Score
Get a 7-Day Free Trial Premium Member Only Premium Member Only 2.14 -0.04 -1.82 -3.19 -2.76

Ocular Therapeutix Quarterly Data
Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23
Beneish M-Score Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -3.19 -3.53 -2.87 -3.03 -2.76

Competitive Comparison of Ocular Therapeutix's Beneish M-Score

For the Biotechnology subindustry, Ocular Therapeutix's Beneish M-Score, along with its competitors' market caps and Beneish M-Score data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Ocular Therapeutix's Beneish M-Score Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Ocular Therapeutix's Beneish M-Score distribution charts can be found below:

* The bar in red indicates where Ocular Therapeutix's Beneish M-Score falls into.



Ocular Therapeutix Beneish M-Score Calculation

The M-score was created by Professor Messod Beneish. Instead of measuring the bankruptcy risk (Altman Z-Score) or business trend (Piotroski F-Score), M-score can be used to detect the risk of earnings manipulation. This is the original research paper on M-score.

The M-Score Variables:

The M-score of Ocular Therapeutix for today is based on a combination of the following eight different indices:

M=-4.84+0.92 * DSRI+0.528 * GMI+0.404 * AQI+0.892 * SGI+0.115 * DEPI
=-4.84+0.92 * 1.0816+0.528 * 1.0024+0.404 * 0.5419+0.892 * 1.135+0.115 * 0.749
-0.172 * SGAI+4.679 * TATA-0.327 * LVGI
-0.172 * 0.9097+4.679 * -0.077374-0.327 * 0.7347
=-2.76

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

This Year (Dec23) TTM:Last Year (Dec22) TTM:
Total Receivables was $26.18 Mil.
Revenue was 14.801 + 15.081 + 15.186 + 13.374 = $58.44 Mil.
Gross Profit was 13.415 + 13.704 + 13.882 + 12.16 = $53.16 Mil.
Total Current Assets was $232.24 Mil.
Total Assets was $252.06 Mil.
Property, Plant and Equipment(Net PPE) was $18.21 Mil.
Depreciation, Depletion and Amortization(DDA) was $2.98 Mil.
Selling, General, & Admin. Expense(SGA) was $74.49 Mil.
Total Current Liabilities was $34.90 Mil.
Long-Term Debt & Capital Lease Obligation was $81.80 Mil.
Net Income was -29.22 + -0.516 + -20.682 + -30.318 = $-80.74 Mil.
Non Operating Income was -6.478 + 20.912 + 1.131 + -6.564 = $9.00 Mil.
Cash Flow from Operations was -22.454 + -7.732 + -20.075 + -19.973 = $-70.23 Mil.
Total Receivables was $21.33 Mil.
Revenue was 14.075 + 11.965 + 12.266 + 13.187 = $51.49 Mil.
Gross Profit was 13.063 + 10.892 + 11.111 + 11.887 = $46.95 Mil.
Total Current Assets was $129.63 Mil.
Total Assets was $149.29 Mil.
Property, Plant and Equipment(Net PPE) was $17.90 Mil.
Depreciation, Depletion and Amortization(DDA) was $2.11 Mil.
Selling, General, & Admin. Expense(SGA) was $72.15 Mil.
Total Current Liabilities was $31.40 Mil.
Long-Term Debt & Capital Lease Obligation was $62.68 Mil.




1. DSRI = Days Sales in Receivables Index

Measured as the ratio of Revenue in Total Receivables in year t to year t-1.

A large increase in DSR could be indicative of revenue inflation.

DSRI=(Receivables_t / Revenue_t) / (Receivables_t-1 / Revenue_t-1)
=(26.179 / 58.442) / (21.325 / 51.493)
=0.447948 / 0.414134
=1.0816

2. GMI = Gross Margin Index

Measured as the ratio of gross margin in year t-1 to gross margin in year t.

Gross margin has deteriorated when this index is above 1. A firm with poorer prospects is more likely to manipulate earnings.

GMI=GrossMargin_t-1 / GrossMargin_t
=(GrossProfit_t-1 / Revenue_t-1) / (GrossProfit_t / Revenue_t)
=(46.953 / 51.493) / (53.161 / 58.442)
=0.911833 / 0.909637
=1.0024

3. AQI = Asset Quality Index

AQI is the ratio of asset quality in year t to year t-1.

Asset quality is measured as the ratio of non-current assets other than Property, Plant and Equipment to Total Assets.

AQI=(1 - (CurrentAssets_t + PPE_t) / TotalAssets_t) / (1 - (CurrentAssets_t-1 + PPE_t-1) / TotalAssets_t-1)
=(1 - (232.235 + 18.211) / 252.06) / (1 - (129.627 + 17.898) / 149.289)
=0.006403 / 0.011816
=0.5419

4. SGI = Sales Growth Index

Ratio of Revenue in year t to sales in year t-1.

Sales growth is not itself a measure of manipulation. However, growth companies are likely to find themselves under pressure to manipulate in order to keep up appearances.

SGI=Sales_t / Sales_t-1
=Revenue_t / Revenue_t-1
=58.442 / 51.493
=1.135

5. DEPI = Depreciation Index

Measured as the ratio of the rate of Depreciation, Depletion and Amortization in year t-1 to the corresponding rate in year t.

DEPI greater than 1 indicates that assets are being depreciated at a slower rate. This suggests that the firm might be revising useful asset life assumptions upwards, or adopting a new method that is income friendly.

DEPI=(Depreciation_t-1 / (Depreciaton_t-1 + PPE_t-1)) / (Depreciation_t / (Depreciaton_t + PPE_t))
=(2.109 / (2.109 + 17.898)) / (2.983 / (2.983 + 18.211))
=0.105413 / 0.140747
=0.749

Note: If the Depreciation, Depletion and Amortization data is not available, we assume that the depreciation rate is constant and set the Depreciation Index to 1.

6. SGAI = Sales, General and Administrative expenses Index

The ratio of Selling, General, & Admin. Expense(SGA) to Sales in year t relative to year t-1.

SGA expenses index > 1 means that the company is becoming less efficient in generate sales.

SGAI=(SGA_t / Sales_t) / (SGA_t-1 /Sales_t-1)
=(74.489 / 58.442) / (72.145 / 51.493)
=1.27458 / 1.401064
=0.9097

7. LVGI = Leverage Index

The ratio of total debt to Total Assets in year t relative to yeat t-1.

An LVGI > 1 indicates an increase in leverage

LVGI=((LTD_t + CurrentLiabilities_t) / TotalAssets_t) / ((LTD_t-1 + CurrentLiabilities_t-1) / TotalAssets_t-1)
=((81.803 + 34.896) / 252.06) / ((62.684 + 31.395) / 149.289)
=0.462981 / 0.63018
=0.7347

8. TATA = Total Accruals to Total Assets

Total accruals calculated as the change in working capital accounts other than cash less depreciation.

TATA=(IncomefromContinuingOperations_t - CashFlowsfromOperations_t) / TotalAssets_t
=(NetIncome_t - NonOperatingIncome_t - CashFlowsfromOperations_t) / TotalAssets_t
=(-80.736 - 9.001 - -70.234) / 252.06
=-0.077374

An M-Score of equal or less than -1.78 suggests that the company is unlikely to be a manipulator. An M-Score of greater than -1.78 signals that the company is likely to be a manipulator.

Ocular Therapeutix has a M-score of -2.76 suggests that the company is unlikely to be a manipulator.


Ocular Therapeutix Beneish M-Score Related Terms

Thank you for viewing the detailed overview of Ocular Therapeutix's Beneish M-Score provided by GuruFocus.com. Please click on the following links to see related term pages.


Ocular Therapeutix (Ocular Therapeutix) Business Description

Traded in Other Exchanges
Address
24 Crosby Drive, Bedford, MA, USA, 01730
Ocular Therapeutix Inc is a biotechnology company that specializes in therapies for diseases and conditions of the eye. The company uses its proprietary hydrogel platform technology to deliver therapeutic agents to the eye. Its pipeline consists of eye medication that aims to overcome the limitations of current eye-drop-based therapies for ophthalmic diseases and conditions. Ocular Therapeutix aims to offer medication to replace the existing eye-drop therapy regimen, with the aim of lasting weeks or months with a one-time product application. Its pipeline product includes Dextenza, OTX-TIC, OTX-TKI, and OTX-IVT.
Executives
Summer Road Llc 10 percent owner 207 6TH STREET, WEST PALM BEACH FL 33401
Antony C. Mattessich director C/O OCULAR THERAPEUTIX, INC., 34 CROSBY DR., SUITE 105, BEDFORD MA 01730
Adrienne L Graves director 125 STONE MOUNTAIN CIRCLE, NAPA CA 94558
Rabia Gurses Ozden officer: Chief Medical Officer C/O AKOUOS, INC., 645 SUMMER STREET SUITE 200, BOSTON MA 02210
Philip C. Strassburger officer: General Counsel 24 CROSBY DRIVE, BEDFORD MA 01730
Donald Notman officer: Chief Financial Officer C/O OCULAR THERAPEUTIX, INC., 15 CROSBY DRIVE, BEDFORD MA 01730
Christopher G White officer: Chief Business Officer C/O AMAG PHARMACEUTICALS, INC., 1100 WINTER STREET, WALTHAM MA 02451
Jeffrey S. Heier director C/O OCULAR THERAPEUTIX, INC., 34 CROSBY DR., SUITE 105, BEDFORD MA 01730
Merilee Raines director IDEXX LABORATORIES, INC., ONE IDEXX DRIVE, WESTBROOK ME 04092
Lindstrom Richard L Md director 2811 WESTWOOD PL, WAYZATA MN 55391
Opaleye Management Inc. 10 percent owner ONE BOSTON PLACE, SUITE 2600, BOSTON MA 02108
Patricia Kitchen officer: Chief Operations Officer C/O OCULAR THERAPEUTIX, INC., 15 CROSBY DRIVE, BEDFORD MA 01730
Leslie J. Williams director C/O OCULAR THERAPEUTIX, INC., 15 CROSBY DRIVE, BEDFORD MA 01730
Seung Suh Hong director C/O OCULAR THERAPEUTIX, INC., 15 CROSBY DRIVE, BEDFORD MA 01730
Amarpreet Sawhney director, 10 percent owner, officer: President and CEO C/O OCULAR THERAPEUTIX, INC., 36 CROSBY DRIVE, SUITE 101, BEDFORD MA 01730

Ocular Therapeutix (Ocular Therapeutix) Headlines

From GuruFocus

Ocular Therapeutix� To Report Second Quarter 2022 Financial Results

By Business Wire Business Wire 07-25-2022